Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) is a clinical‑stage biotechnology company focused on the discovery, validation, and development of first‑in‑class T‑cell engager (TCE) and antibody‑drug conjugate (ADC) therapeutics through OGAP®‑Verify platform, a quantitative, proteomics‑driven mass spectrometry system. OGAP® enables the identification and quantification of plasma membrane proteins from cancer patient biopsies down to ~50 copies per cell—significantly exceeding that of IHC. OBT offers an integrated TCE and ADC platform spanning target discovery through to IND submission. Leveraging its extensive dataset, OBT systematically maps tumour‑associated antigen (TAA) pairs to enable both “AND” and “OR” multispecific targeting strategies. The technology is validated through partnerships with BMS, Roche, GSK, and Boehringer Ingelheim. OBT currently has four clinical‑stage programmes, with partnered assets advancing across Phase III (OBT620/obrixtamig), Phase II, and Phase I.
